^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    UD TGFbetai NK cells

    i
    Other names: UD TGFbetai NK cells
    Associations

    News

    Trials
    Company:
    The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    11ms
    NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Recruiting, Elvira Umyarova | Not yet recruiting --> Recruiting
    Enrollment open • Immune cell
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    12ms
    Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Elvira Umyarova
    New P1 trial • Immune cell
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    1year
    Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Margaret Gatti-Mays | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
    1year
    Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Margaret Gatti-Mays
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
    1year
    Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer (clinicaltrials.gov)
    P1b/2, N=42, Recruiting, Margaret Gatti-Mays | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • TGFBI (Transforming Growth Factor Beta Induced)
    |
    HER-2 negative
    |
    gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
    almost2years
    Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Kari Kendra | Not yet recruiting --> Recruiting
    Enrollment open • Preclinical • Combination therapy • Metastases
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    temozolomide • UD TGFbetai NK cells
    2years
    Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Kari Kendra
    New P1/2 trial • Preclinical • Combination therapy • Metastases
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    temozolomide • UD TGFbetai NK cells